Glycophorin C in carotid atherosclerotic plaque reflects intraplaque hemorrhage and pre-procedural neurological symptoms.

Joost M. Mekke[a], Tim R. Sakkers[b], Maarten C. Verwer[a], Noortje A.M. van den Dungen[c], Y. Song[e], C. Miller[d,e,f,] Aloke V Finn[g], Gerard Pasterkamp[c], Michal Mokry[b,h], Hester M. den Ruijter[b], Aryan Vink[i], Dominique P. V. de Kleijn[a,j], Gert J. de Borst[a], Saskia Haitjema[b*], Sander W. van der Laan[b*]

Affiliations

[a] Department of Vascular Surgery, Division of Surgical Specialties, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

[b] Laboratory of Experimental Cardiology, Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, University Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands

[c] Central Diagnostic Laboratory, Division Laboratories and Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

[d] Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA

[e] Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA 22908, USA

[f] Department of Public Health Sciences, University of Virginia, Charlottesville, VA 22908, USA

[g] CV Path Institute, Gaithersburg, MD 20878 USA

[h] Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, University Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands

[i] Department of Pathology, University Medical Center Utrecht, University Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands

[j] Netherlands Heart Institute, Moreelsepark 1, 3511 EP, Utrecht, The Netherlands

*Shared last authorship

In this paper 7 figures and one table can be found.

Address for correspondence

Sander W. van der Laan, PhD

Central Diagnostics Laboratory, University Medical Center Utrecht, Utrecht University

Heidelberglaan 100, 3584 CX Utrecht, the Netherlands

E: s.w.vanderlaan-2@umcutrecht.nl

T: +31 88 756 76 96 Twitter: @swvanderlaan

Abstract

Background and aims

The accumulation of erythrocyte membranes within an atherosclerotic plaque may contribute to the deposition of free cholesterol and thereby the enlargement of the necrotic core. Erythrocyte membranes can be visualized and quantified in the plaque by immunostaining for the erythrocyte marker glycophorin C. We therefore hypothesized, that glycophorin C is a marker for plaque vulnerability and may therefore reflect intraplaque hemorrhage (IPH), vulnerability of plaques and predict pre-procedural neurological symptoms.

Methods

We quantified glycophorin C in human atherosclerotic plaque samples from 1,819 consecutive asymptomatic and symptomatic patients undergoing carotid endarterectomy from the Athero-Express Biobank with the `slideToolKit` method.

Results

The prevalence of IPH was 62.4%, and the prevalence of pre-procedural neurological symptoms was 87.1%. The percentage glycophorin staining was significantly higher in male patients compared to female patients (median 7.15 (IQR:3.37, 13.41) versus median 4.06 (IQR:1.98, 8.32), p<0.001). Quantified glycophorin C was associated with IPH (OR 1.90; 95% CI 1.63, 2.21; p=<0.001) when corrected for clinical confounders. Glycophorin C was significantly associated with ipsilateral pre-procedural neurological symptoms (OR:1.27, 95%CI:1.06-1.41, *p*=0.005), and upon sex-stratified analyses, specifically in male patients (OR 1.37; 95%CI 1.12, 1.69; p=0.003), but not in female patients (OR 1.15; 95%CI 0.77, 1.73; p=0.27). Glycophorin was associated with classical features of a vulnerable plaque, such as a larger lipid core (OR 1.85; 95%CI 1.60, 2.15; p<0.001), a higher macrophage burden (OR 1.87; 95%CI 1.63, 2.14; p<0.001), less calcifications (OR 0.81; 95%CI 0.71, 0.91; p<0.001), a lower collagen and SMC content (OR 0.70; 95%CI 0.60, 0.82; p<0.001 and OR 0.60; 95%CI 0.52, 0.68; p<0.001, respectively). There were marked sex differences, in male patients

glycophorin was associated with calcifications and collagen (OR 0.75; 95%CI 0.64, 0.87; p<0.001 and OR 0.65; 95%CI 0.53, 0.79; p<0.001, respectively) while these associations were not found in female patients.

Conclusions

Quantified glycophorin C was independently associated with the presence of IPH, symptomatic preprocedural symptoms in male, and with a more vulnerable plaque composition in both women and men. Which strengthens the hypothesize that plaque glycophorin C is a marker of plaque vulnerability.

Keywords

Atherosclerosis, Carotid endarterectomy, Glycophorin, Intraplaque hemorrhage, Plaque instability, Sex.

Introduction

Atherosclerotic plaque features contribute to plaque instability. These features are among others: a large lipid core, a thin fibrous cap, a large infiltrate of pro-inflammatory cells, neovascularization and the presence of intraplaque hemorrhage (IPH)[1,2]. These features are a result of processes contributing to the conversion of stable, asymptomatic lesion to an unstable, rupture prone or ruptured plaque, of which inflammation, cellular apoptosis and expansion of the lipid-rich necrotic core are the most studied[2].

Also, the death of macrophages and smooth-muscle foams cells are major contributors to the expansion of the lipid core[3]. More recently IPH was identified to be a major contributor to the accumulation of extracellular free cholesterol within unstable plaques. This was thought to be largely due the accumulation of extravasated erythrocytes[4]. Due to their high cholesterol content in their membranes, which exceeds that of all other cells in the body with lipids constituting 40% of their weight, erythrocytes were found to be capable of providing a substantial amount of lipids to the necrotic core[5]. Immunostaining against glycophorins has been used to identify intact erythrocytes and membrane remnants of erythrocytes in atherosclerotic plaque and is therefore able to visualize previous hemorrhages in plaques[4]. Glycophorins are erythrocyte specific membrane proteins that represent about 2% of the erythrocyte membrane proteins, of whom glycophorin A is the most prevalent with $5\sim9\times10^5$ copies per cell, while glycophorin C is present in lower amounts, with approximately $0.5\sim1.0\times10^5$ copies in each red blood cell[6].

Previous smaller studies have used a similar approach to quantify erythrocyte membranes by staining for glycophorin A, but instead of using a continuous scale, a semi quantitatively graded subjective score was used with a scale from zero to four, with higher scores indicating higher percentages[4,7], or as a ratio of glycophorin positive area/vessel area[8]. In these studies, higher glycophorin scores were associated with advanced plaque and (unstable) plaque features such as a large necrotic core, neovascularization, calcification, and macrophage infiltration[4,7]. A large sample size study, however,

has not been performed. To accommodate large samples and overcome the drawbacks of the inter- and intra-observer variability of manual assessment methods[9,10], the `slideToolKit` method was developed[11]. With this method, the total area of glycophorin C can be quantified using a fully automated whole slide analysis technique (WSI), which is less labor-intensive, more accurate and reproducible[12].

We hypothesized that glycophorin C is a marker for plaque vulnerability and is associated with intraplaque hemorrhage (IPH) and pre-procedural neurological symptoms. Furthermore, in this study, we explored the association of glycophorin with other binary plaque characteristics, such as lipid core, macrophage- and smooth muscle content, to examine its effect on the plaque composition stratified by sex. Finally, we associated glycophorin C with secondary major adverse cardiovascular events (MACE) within three-years of follow up. We performed a separate sex stratification to account for sex differences; previous work by our group has shown that IPH is a predictor of future cardiovascular events only in male patients and occurs more frequently in male patients[13].

Materials and methods

Study population

We used human atherosclerotic plaques collected in the Athero-Express Biobank (www.atheroexpress.nl) (**Figure 1B**), an ongoing prospective study of patients undergoing carotid endarterectomy (CEA) for atherosclerotic carotid stenosis[14]. Indications for CEA were reviewed by a multidisciplinary vascular team according to ESVS guidelines[15]. Patients were recruited from the St. Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands and University Medical Center Utrecht in Utrecht, the Netherlands from 2002 onwards. Individuals who agreed to participate completed standardized baseline questionnaires regarding cardiovascular risk factors, medical history and medication use prior to surgery, that were verified against medical records. Pre-operative blood samples were collected, processed and stored for future use. Plaque samples were freshly obtained during surgery and analyzed as described below. The current study was conducted in accordance with the Declaration of Helsinki and was approved by the ethical boards of both hospitals. All patients provided written informed consent.

Atherosclerotic plaque processing

CEA derived plaque samples were immediately transferred and processed (**Figure 1A**). The plaque was divided in parallel segments of 5-mm thickness perpendicular to the arterial axis and the segment with the greatest plaque burden, the culprit lesion, was subjected to histopathological examination, as previously described[10,16]. In short, the culprit lesion was washed to remove presumed artifacts of the surgery such as red blood cells surrounding the dissection planes and fixed the culprit lesion in 4% formaldehyde, subsequently decalcified, embedded in paraffin and cut into 5 μm sections that were routinely stained for different characteristics, which was scored manually by a single experienced observer as no/minor or moderate/heavy staining according to predefined criteria using a microscope with 40x magnification[16]. The Hematoxylin-Eosin (H&E) was used to obtain a general overview to assess any calcification(s) and the lipid core, picrosirius red and elastin von Gieson stainings were used to score collagen, the alpha-actin staining was used for smooth muscle cells (SMCs) and the CD68 staining for macrophages. The presence of intraplaque hemorrhage (IPH) was defined as

hemorrhage within the plaque tissue and was rated as being absent or present using H&E and Fibrin staining. Intra-observer and interobserver variability has been examined previously and showed moderate to good reproducibility (κ 0.6-0.9) for the semi-quantitative scoring method[10].

Glycophorin staining

We used glycophorin C because this antibody has been routinely used in the automatic staining machine for immunohistochemistry of the diagnostic pathology laboratory of the University Medical Center Utrecht in hematopathology diagnostics. In this way we could guarantee that the staining was stable and has the same staining conditions in all slides of the study population. Although glycophorin A is more abundant with 5-9x10^5 copies, than the 0.5-1.0x10^5 copies of glycophorin C per cell, both give the same staining pattern of (remnants of) erythrocyte membranes due to the high prevalence of copies[17]**.** To visualize glycophorin C, sections were stained with a monoclonal mouse anti-Glycophorin C antibody (clone Ret40f, DAKO, dilution 1:800) using the Ventana BenchMark Ultra system (Roche Diagnostics) with CC1 (EDTA) pretreatment during 24 minutes. The plaque characteristic glycophorin C was defined as the total area in μm^2 positive for the respective stain.

ExpressScan: histopathological analysis of atherosclerotic plaque characteristics

We used the `slideToolKit` (https://github.com/swvanderlaan/slideToolKit) to quantify the amount of glycophorin staining on culprit lesions from carotid atherosclerotic plaque samples. The `slideToolKit` workflow has been published previously and involves a four-step process using a collection of open-source scripts to support the analyses of whole slide images (WSIs)[11,12]. WSIs are slides that are completely scanned at high magnification and stored as digital images, also known as WSI or digital slides. In short, in step one (*acquisition*), the WSIs were obtained and stored. To this end, we set up the ExpressScan to scan all stained sections using a Roche Ventana iScan HT slide scanner or a Hamamatsu C12000-22 Digital slide scanner and saved brightfield microscopy WSIs as z-stacked TIF (Ventana) and NDPI (Hamamatsu), sized ~300Mb to ~1.1Gb each. In the second step (*preparation*), the files of a give stain were organized into stain-folders and all individual images

*sub*folders within that stain-folder. To increase downstream analytical efficiency, the non-tissue parts of the images were masked (blackened) to enable exclusion during the next two steps. In the third step, the WSIs were divided into tiles (tiling), which created tiled images of manageable size for later analysis. In the fourth and final step (analysis), the tiled WSIs were analyzed using custom pre-trained pipelines (protocols) using CellProfiler v4.1.3[11]; results were stored and combined in a comma-separated dataset. For glycophorin C a pipeline was created to assess and quantify the total tissue surface that was positively stained for the respective stain. Analysis pipelines are available in the `slideToolKit` repository in the folder `pipeLines`. See **Supplemental Figure 1** for the Glycophorin C `CellProfiler` pipeline workflow using a single tile as an example. The main strengths of the `slideToolKit` method are that it is fully automated, precise and scores excellent regarding reproducibility with intraclass correlation coefficients (ICCs) of 0.92-0.97[12].

Ipsilateral pre-procedural neurological symptoms

Patients were classified with either an ipsilateral asymptomatic or ipsilateral symptomatic carotid stenosis prior to surgery, based on their answers to a standardized questionnaire regarding that were verified by a review of their medical history. Patients without any ipsilateral symptoms in the last six months were classified as asymptomatic. Cerebrovascular events included ischemic stroke, a transient ischemic attack (TIA), amaurosis fugax, ocular ischemic syndrome or a central retinal artery occlusion.

Follow-up analysis for major adverse cardiovascular events (MACE)

MACE was defined as the three-year postoperative risk of major adverse cardiovascular events including fatal or nonfatal ischemic or hemorrhagic stroke, fatal or nonfatal myocardial infarction (MI) and any vascular death, defined as death of presumed vascular origin. Clinical endpoints were assessed at one, two and three years after surgery by means of patient questionnaires and validated by review of medical records; if necessary, general practitioners or other treating physicians were contacted for follow-up data.

Statistical analysis

Continuous variables were summarized as mean and standard deviation (SD) or as median and interquartile range (IQR). Categorical variables were expressed as frequencies and percentages. Glycophorin C and the total plaque size were inverse-rank transformed to standardize the data. Continuous data was assessed for skewness and natural log transformed in analysis when needed. Logistic regression analyses were performed to test the association between glycophorin and IPH, pre-procedural neurological symptoms and binary plaque characteristics. For the association between glycophorin and secondary MACE Cox proportional hazard models were performed. We have sex stratified the main results.

For the logistic regression models and Cox proportional hazard models (Survival package) we made two different models according to a specific structure, Model 1 adjusted for plaque size, Model 2 adjusted for plaque size and (potential) confounders. The confounders were identified by exploring the association of baseline characteristic, such as risk factor and medication use, with glycophorin adjusted for plaque size, and with the different dependent outcome variables (e.g., IPH and MACE). When the baseline characteristic was associated with the quantified plaque characteristic and with the outcome variable with a p-value of <0.1, the specific baseline characteristic was included as a potential confounder in the final logistic regression or Cox proportional hazards model, respectively. Across the selected potential confounders, the proportion of missing values was analyzed (**Supplemental Table 1**). Missing values of potential confounders were imputed using multivariate imputation by chained equations[18] (mice package). When correlated predictors were included in the final model, the best model was selected based on the Akaike Information Criterion (AIC).

Statistical significance threshold was set at a two-sided *p*-value <0.05 across all analyses. Analyses were performed using R (v4.0.5; The R Foundation for Statistical Computing).

Data and code availability

The data as used here are available through DataverseNL. DOI: https://doi.org/10.34894/08TUBV

All documented code can be found

herehttps://github.com/CirculatoryHealth/ExpressScan_Glycophorin

Results

Study population

A total of 1,819 CEA patients from the Athero-Express Biobank were included in the current analysis (mean age 69±9 years, 29.8% female, 87.1% symptomatic presentation, **Table 1**). Most patients had one or multiple cardiovascular comorbidities such as hypertension (75%), hypercholesterolemia (70%), diabetes (25%), or a history of coronary artery disease (CAD, 33%). Female patients were more often diagnosed with hypertension, had significantly higher levels of total cholesterol, LDL and HDL, a significantly worse kidney function, were more often smokers and were more likely to be diagnosed with a critical carotid stenosis (70-99%), but less likely have a history of CAD, when compared with male patients (**Table 1**). Moreover, the total plaque area covered by glycophorin C staining, expressed as percentage glycophorin staining was significantly higher in male patients compared to female patients (**Table 1**).

Glycophorin C staining

Glycophorin C was used for staining and visualization of erythrocytes and erythrocyte membranes in atherosclerotic plaque. The slides showed apparent differences between male and females (**Figure 2**). In addition, in certain samples with high glycophorin C staining, the distribution of erythrocytes was diffuse rather than concentrated at one specific location in the plaque (**Figure 2**).

Glycophorin and intraplaque hemorrhage

In general, plaques with greater total plaque area covered with glycophorin C, expressed as percentage staining, were plaques with intraplaque hemorrhage as scored semi-quantitatively (3.70 (IQR: 1.74, 7.27), 6.99 (IQR 3.12, 13.26), $p<0.001$, **Figure 3, Methods**). However, some outliers were observed that contained a large area stained for glycophorin C but were previously scored as plaques without intraplaque hemorrhage using semi-quantitative staining method. We also observed this in the histological slides stained for glycophorin (**Figure 4**).

Glycophorin C adjusted for plaque size was associated with the presence of IPH in atherosclerotic plaques (Model 1: OR 1.83; 95% CI 1.59, 2.12; p=<0.001, **Figure 5A**). After adjustments for confounders the association remained significant (Model 2: OR 1.90; 95% CI 1.63, 2.21; p=<0.001). In separate sex-stratified, similar associations were found with adjusted logistic regression analysis in male patients (Model 2: OR 1.85; 95% CI 1.53, 2.26; p=<0.001) and in female patients (Model 2: OR 1.43; 95%CI 1.12, 1.84; p=0.004, **Figure 5A**).

Glycophorin C and pre-procedural neurological symptoms

Overall, glycophorin C was found to be associated with neurological symptoms before CEA after correcting for plaque size (Model 1: OR 1.33; 95%CI 1.12, 1.57; p<0.001), the association remained significant after correction for multiple confounding variables (Model 2: OR 1.34; 95%CI 1.11, 1.62; p=0.002) (**Figure 5B**). In the separate sex-stratified analysis, a similar association was found in male patients but not in female patients (Model 2: OR 1.37; 95%CI 1.12, 1.69; p=0.003 and Model 2: OR 1.15; 95%CI 0.77, 1.73; p=0.27, respectively) (**Figure 5B**).

Glycophorin C and overall plaque phenotype

The total plaque surface covered by glycophorin C expressed as a percentage was associated with the overall plaque phenotype. Overall, a gradual increase in glycophorin C staining was seen in fibroatheromatous and atheromatous plaques in comparison to fibrous plaques (**Figure 6, Supplemental Table 3)**. The percentage of glycophorin C was significantly higher in fibroatheromatous and atheromatous plaques in comparison to fibrous plaques (p=8.8x10^{-12} and p<2.10x10^{-16}, respectively, **Figure 6**). Additionally, the percentage of glycophorin C was significantly higher in atheromatous plaques in comparison to fibroatheromatous plaques (p=3.4x10^{-8}, **Figure 6**).

Associations with histological plaque characteristics

Besides its strong correlation with IPH, glycophorin adjusted for plaque size was also associated with a large lipid core (OR 1.85; 95%CI 1.60, 2.15; p<0.001) and a higher macrophage burden (OR 1.87; 95%CI 1.63, 2.14; p<0.001, **Figure 7**). In addition, glycophorin adjusted for plaque size was

associated with less calcifications (OR 0.81; 95%CI 0.71, 0.91; p<0.001), a lower collagen content (OR 0.70; 95%CI 0.60, 0.82; p<0.001) and lower SMC content (OR 0.60; 95%CI 0.52, 0.68; p<0.001) (**Figure 7**). The separate sex stratified analysis identified apparent sex differences in the associations of glycophorin with large lipid core, calcifications, collagen content, macrophage burden and intraplaque hemorrhage (**Figure 7**). In female patients glycophorin was not associated with calcifications and collagen content (OR 1.07; 95%CI 0.85,1.35; *p*=0.57 and OR 0.83; 95%CI 0.62,1.12; *p*=0.21, respectively) while in male patients the associations were similar to the full cohort (**Figure 6**). In addition, the effect sizes of the association between glycophorin and macrophage burden and intraplaque hemorrhage were lower in female patients compared to male patients (OR 1.45; 95% 1.14,1.86 *p*=0.003 vs. OR 2.01; 95% 1.70, 2.39 *p*<0.001 and OR 1.43; 95% 1.12,1.84 *p*=0.005 vs. OR 1.99; 95% 1.67, 2.39 *p*<0.001, respectively) (**Figure 6**).

Glycophorin and major adverse cardiovascular events

Glycophorin was not associated with MACE in Cox regression analysis adjusted for plaque size (Model 1: HR 1.15; 95%CI 0.98, 1.35; p=0.09) nor in a model adjusted for plaque size and confounding baseline variables (Model 2: HR 1.14; 95%CI 0.95, 1.35; p=0.16) (**Figure 5C**). The sex-stratified analysis showed no association between glycophorin and future MACE in male or female patients separately (**Figure 5C**).

Post-hoc analysis: Intraplaque hemorrhage and major adverse cardiovascular events

Univariably IPH was associated with MACE in a Cox regression analysis (Model 1, **Supplemental Figure 3**). After adjusting for confounders, the association between IPH and MACE remained significant (Model 2, **Supplemental Figure 3**), which was also the case in male patients but not in female patients (**Supplemental Figure 3**).

Discussion

In the present study, we showed that glycophorin C was associated with the presence of IPH, a potent marker for future MACE[16,19] in patients that underwent CEA. Moreover, glycophorin C was associated with pre-procedural neurological symptoms which strengthens our hypothesis that glycophorin C is a marker for plaque vulnerability. Furthermore, this is reinforced in the current paper by the significant gradual increase in glycophorin C staining in more advanced plaque phenotypes. In addition, glycophorin C was found to be associated with classical features of a vulnerable plaque[20], meaning a larger lipid core, a higher macrophage burden, a lower collagen content and a lower SMC content. In the sex-stratified analyses, we observed sex differences with regard to calcifications and collagen. This is in line with previous findings in other small-scale studies.

Multiple mechanisms have been described that could explain how erythrocytes accumulate in plaque, via plaque fissures[21], via incorporation of a luminal erythrocyte-rich thrombus into the plaque[22] and the most probable mechanism via leaky newly formed microvessels[23]. This is because the micro vessels are lined with discontinuous abnormal endothelial cells that allow the extravasation of leukocytes and erythrocytes[24]. The pro-inflammatory and pro-oxidative environment makes the erythrocytes vulnerable to hemolysis or phagocytosis by intraplaque macrophages and SMC[25]. As a result, erythrocyte components such as cholesterol, iron, heme and hemoglobin molecules are released. Due the high cholesterol content of erythrocyte membranes, of which lipids account for 40% by weight[5], erythrocyte membranes can deliver a significant amount of lipids to the necrotic core. Iron, heme and hemoglobin have been shown to trigger processes that contribute to plaque instability, including endothelial activation and dysfunction, SMC proliferation and migration, foam cell formation, platelet aggregation and macrophage activation[26–28]. Together, the accumulation of erythrocyte membranes and subsequent processes within an atherosclerotic plaque represent a powerful atherogenic stimulus. This was confirmed in an animal experiment in which autologous erythrocytes were directly injected in stable atherosclerotic lesions in the aorta of rabbits[4]. Erythrocyte injection triggered the enlargement of necrotic core and formation of free cholesterol crystals along

with excessive macrophage infiltration[4]. As such, erythrocyte accumulation quantified by glycophorin staining, may represent a marker of atherosclerotic evolution towards a plaque with a 'vulnerable' phenotype. This is supported by the significant gradual increase in glycophorin C staining in more advanced plaque phenotypes (**Figure 6**).

In the current study, we found as association between sex with quantified glycophorin C. Similarly, we found that glycophorin C only associated with pre-procedural neurological symptoms in men but not in women. The underlying mechanism that explains sex-related differences in plaque composition is yet to be unraveled, however evidence that the plaque composition differs between men and women is accumulating[29]. Iliofemoral plaques from men had a higher prevalence of lipid cores and plaque hemorrhage compared to women[30]. A large coronary computed tomography angiography (CTA) study revealed that plaque from men had a higher prevalence of high-risk plaque features on CTA and that plaque from men were more heavily calcified[31], the latter was also found in autopsy study[32]. In addition, plaque from women demonstrate more superficial erosions than plaque ruptures, that could increase coagulability via apoptosis of endothelial cells and activation of circulating tissue factor[33,34]. In the sex-stratified analysis of the associations of glycophorin with semi-quantitative scored plaque characteristics, we also found marked differences between male and female patients. Glycophorin C was not associated with calcifications and collagen in female patients, this might either be due to lower levels of glycophorin C in female patients as demonstrated in the current paper or that plaques of female patients generally contain more calcifications or collagen[29]. The differences in plaque composition between men and women may provide a possible explanation for the differences in clinical outcome between men and women.

Despite a strong association between glycophorin and IPH, glycophorin was not identified as an independent predictor of future cardiovascular events. In a post-hoc analysis, we confirmed that this was still the case for IPH, as it was in a previous study by our group[13]. In this previous study, we showed that sex was associated with IPH and that carotids from men showed a significantly higher prevalence of IPH compared with women[13]. The location within a plaque is considered with scoring

the presence of IPH, however this does not influence the quantification of glycophorin C. This might be an explanation why we did not find an association between glycophorin C and future MACE, but did find an association between IPH and future MACE. Plaques with diffuse staining for glycophorin C in a culprit lesion might not be as vulnerable when compared to the same amount of staining located near neo-vessels or concentrated at a more vulnerable location within the plaque. Further, we observed discrepencies between the automated assessment of Glycophorin C and the semi-quantitatively scored IPH, showing that manual assessment of WSI is prone to observer variability and herrant human interpretation.

There are a few limitations in the present study. First as the Athero-Express Biobank represents a retrospective study design, we can only speculate about the causality of our findings. Second, as discussed in our previous work, intraplaque hemorrhage might not be the right term, as endarterectomy specimens are frequently fragmented it is difficult to determine the exact source of plaque hemorrhage, they might be due to plaque bleeding at the luminal site due plaque disruption or as a result of defective leaky micro vessels[16,35]. However, the hemorrhages revealed signs of organization during assessment, this did indicate that the plaque hemorrhage are not artifacts of surgical dissection[16]. Third, the new method quantitatively scores the positively stained plaque areas regardless of their location within the plaque, these areas can be clustered or diffuse in the plaque. While this may also be an advantage, knowing the region of a stained plaque area within the plaque might also have additional value. Next, the quantitative assessment of the plaque characteristics was based on the analysis of a single whole-slide image (WSI), rather than a serial assessment of various WSIs throughout the plaque. We deem it unlikely that this strongly influences our results, as there was good overall agreement between three- to five-millimeter sections in histological assessment studies using the semi-quantitative classification method[9,10]. However, this may vary depending on the method used and the specific feature of the plaque being scored. Furthermore, although we described one of the largest groups of women operated by CEA, confounding in the multivariable analysis may have been impeded by power, i.e., sample size. These sex-stratified results need to be interpreted in the light of the confidence intervals, to avoid misleading conclusions[36]. In addition, for the

longitudinal analyses we have used MACE as a composite outcome, and we were not able to perform analyses on separate outcomes such as (non)fatal stroke or non(fatal) myocardial infarction due to a limited number of events.

An important strength of our study is that we have shown that staining the accumulation of erythrocytes and erythrocyte remnants with a glycophorin C staining provides additional valuable information in regards to plaque stability. As mentioned, erythrocyte accumulation in the plaque due to leaky microvessels seems to be an atherogenic stimulus. Moreover, this is the first study in which we apply the fully automated method `slideToolKit` on large scale a specific staining. As such, this study confirms of the effectiveness of our `slideToolKit` method, allowing further reliable determination of plaque composition and the exploration of possible new histological (bio)markers, specifically in relation to 'omics' datasets which requires precise phenotyping to reduce noise and spurious associations.

In summary, glycophorin C was independently associated with the presence of IPH and other features of a more vulnerable plaque in both male and female patients and with neurological pre-procedural symptoms in male patients undergoing CEA. However, in female patients glycophorin was not associated twith calcifications and collagen content. These findings support the role of plaque glycophorin as a marker of plaque vulnerability, especially in male patients.

Funding
This work was supported by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation (CVON-GENIUS-2 to GP and SWvdL). We are thankful for the support of the ERA-CVD program 'druggable-MI-targets' (grant number: 01KL1802), the EU H2020 TO_AITION (grant number: 848146), EU H2020 Taxinomisis (grant number 755320 JM, GP, GJB DdK), and the Leducq Fondation 'PlaqOmics'.

Conflict of interest
Dr. Sander W. van der Laan has received Roche funding for unrelated work; Roche had no involvement whatsoever in any aspect of this study.

Dr. Aloke V Finn has received consultant fees/honoraria from Abbott Vascular, Amgen, Biosensors, Boston Scientific, Celonova, Cook Medical, CSI, Lutonix Bard, Sinomed. and Terumo Corporation. They had no involvement whatsoever in any aspect of this study.

AV Finn is an employees of the CVPath Institute which has received GranuResearch/Clinical Trial support from NIH-HL141425, Leducq Foundation Grant, 4C Medical, 4Tech, Abbott Vascular, Ablative Solutions. Absorption Systems, Advanced NanoTherapies, Aerwave Medical, Alivas, Amgen. Asahi Medical, Aurios Medical, Avantec Vascular, BD, Biosensors, Biotronik, Biotyx Medical, Bolt Medical, Boston Scientific, Canon USA, Cardiac Implants, Cardiawave, CardioMech, Celonova, Cerus EndoVascuIar, Chansu Vascular Technologies, Childrens National Medical Center, Concept Medical, Cook Medical, Cooper Health, Cormaze Technologies GmbH, CRL/AcceILab, Croivalue, CSI, Dexcom, Edwards Lifesciences, Elucid Bioimaging, eLum Technologies, Emboline, Endotronix, Envision, Filterlex, Imperative Care, Innovalve, Innovative Cardiovascular Solutions, Intact Vascular, Interface Biolgics, Intershunt Techtnologies, Invatin Technologies, Lahav CRO, Limflow, L&J Biosciences, Lutonix, Lyra Therapeutics, Mayo Clinic, Maywell, MD Start, MedAIIiance, Medanex, Medtronic, Mercator, Microport, Microvention, Neovasc, Nephronyx, Nova Vascular, Nyra Medical, Occultech, Olympus, Ohio Health, OrbusNeich, Ossio, Phenox, Pi-Cardia, Polares Medical, Polyvascular, Profusa, ProKidney LLC, Protembis, Pulse Biosciences, Qool Therapeutics, Recombinetics, Recor Medical, Regencor, Renata Medical, Restore Medical, Ripple Therapeutics, Rush University, Sanofi, Shockwave, Sahajanand Medical Technologies, SoundPipe, Spartan Micro, Spectrawave, Surmodics, Terumo Corporation, The Jacobs Institute, Transmural Systems, Transverse Medical, TruLeaf Medical, UCSF, UPMC, Vesper, Vetex Medical, Whiteswell, WL Gore, and Xeltis.

The Authors declare that there is no conflict of interest.

Author contributions
Study design: JM, DK, GB, SH, SWvdL
Data collection: JM, ND, MV, SWvdL, GP
Sample measurements: ND, YS, CM, SWvdL
Data analysis and interpretation: JM, TS, MV, DK, MM, HR, GP, YS, CM, AF, SH, SWvdL
Drafting the article and figures: JM, MV, DK, GB, SH, SWvdL
Critical revisions and final approval: JM, TS, MV, ND, YS, CM, AF, GP, MM, HR, DK, GB, SH, SWvdL

Acknowledgements
We would also like to thank all the (former) employees involved in the Athero-Express Biobank Study of the Departments of Surgery of the St. Antonius Hospital Nieuwegein and University Medical Center Utrecht for their continuing work. Lastly, we would like to thank all participants of the Athero-Express Biobank Study; without you these kinds of studies would not be possible. AV Finn has received consultant fees/honoraria from Abbott Vascular, Amgen, Biosensors, Boston Scientific, Celonova, Cook Medical, CSI, Lutonix Bard, Sinomed. and Terumo Corporation.

References:

1 Michel JB, Virmani R, Arbustini E, Pasterkamp G. Intraplaque haemorrhages as the trigger of plaque vulnerability. *Eur Heart J* 2011;**32**(16):1977–85. Doi: 10.1093/eurheartj/ehr054.

2 Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. *Nat Rev Dis Prim* 2019;**5**(1):1–18. Doi: 10.1038/s41572-019-0106-z.

3 Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. *Arterioscler Thromb Vasc Biol* 1996:4–11. Doi: 10.1161/01.ATV.16.1.4.

4 Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque Hemorrhage and Progression of Coronary Atheroma. *N Engl J Med* 2003;**349**(24):2316–25. Doi: 10.1056/NEJMoa035655.

5 Kolodgie FD, Burke AP, Nakazawa G, Cheng Q, Xu X, Virmani R. Free cholesterol in atherosclerotic plaques: Where does it come from? *Curr Opin Lipidol* 2007:500–7. Doi: 10.1097/MOL.0b013e3282efa35b.

6 Aoki T. A comprehensive review of our current understanding of red blood cell (RBC) glycoproteins. *Membranes (Basel)* 2017;**7**(4). Doi: 10.3390/membranes7040056.

7 Gössl M, Versari D, Hildebrandt HA, Bajanowski T, Sangiorgi G, Erbel R, et al. Segmental Heterogeneity of Vasa Vasorum Neovascularization in Human Coronary Atherosclerosis. *JACC Cardiovasc Imaging* 2010;**3**(1):32–40. Doi: 10.1016/j.jcmg.2009.10.009.

8 Hao H, Iihara K, Ishibashi-Ueda H, Saito F, Hirota S. Correlation of thin fibrous cap possessing adipophilin-positive macrophages and intraplaque hemorrhage with high clinical risk for carotid endarterectomy: Clinical article. *J Neurosurg* 2011;**114**(4):1080–7. Doi: 10.3171/2010.8.JNS10423.

9 Lovett JK, Gallagher PJ, Rothwell PM. Reproducibility of histological assessment of carotid plaque: Implications for studies of carotid imaging. *Cerebrovasc Dis* 2004;**18**(2):117–23. Doi: 10.1159/000079259.

10 Hellings WE, Pasterkamp G, Vollebregt A, Seldenrijk CA, De Vries J-PPM, Velema E, et al. Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens. *J Vasc Surg* 2007;**46**(6):1147–54. Doi: 10.1016/j.jvs.2007.08.018.

11 Nelissen BGL, van Herwaarden JA, Moll FL, van Diest PJ, Pasterkamp G. SlideToolkit: An Assistive Toolset for the Histological Quantification of Whole Slide Images. *PLoS One* 2014;**9**(11):e110289. Doi: 10.1371/journal.pone.0110289.

12 Vrijenhoek JEP, Nelissen BGL, Velema E, Vons K, de Vries J-PPM, Eijkemans MJC, et al. High Reproducibility of Histological Characterization by Whole Virtual Slide Quantification; An Example Using Carotid Plaque Specimens. *PLoS One* 2014;**9**(12):e115907. Doi: 10.1371/journal.pone.0115907.

13 Vrijenhoek JEP, Den Ruijter HM, De Borst GJ, De Kleijn DPV, De Vries JPPM, Bots ML, et al. Sex is associated with the presence of atherosclerotic plaque hemorrhage and modifies the relation between plaque hemorrhage and cardiovascular outcome. *Stroke* 2013;**44**(12):3318–23. Doi: 10.1161/STROKEAHA.113.002633.

14 Verhoeven BAN, Velema E, Schoneveld AH, Vries JPPM de., de Bruin P, Seldenrijk CA, et al. Athero-express: Differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. *Eur J Epidemiol* 2004;**19**(12):1127–33. Doi: 10.1007/s10564-004-2304-6.

15 Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor's Choice – Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg* 2018;**55**(1):3–81. Doi: 10.1016/j.ejvs.2017.06.021.

16 Hellings WE, Peeters W, Moll FL, Piers S, Van Setten J, Van Der Spek PJ, et al. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: A prognostic study. *Circulation* 2010;**121**(17):1941–50. Doi: 10.1161/CIRCULATIONAHA.109.887497.

17 Cartron JP, Le Van Kim C, Colin Y. Glycophorin C and related glycoproteins: Structure, function, and regulation. Seminars in Hematology. https://pubmed.ncbi.nlm.nih.gov/8480189/.

09/14/2021.
18 van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. *J Stat Softw* 2011;**45**(3):1–67. Doi: 10.18637/jss.v045.i03.
19 Gao P, Chen ZQ, Bao YH, Jiao LQ, Ling F. Correlation between carotid intraplaque hemorrhage and clinical symptoms: Systematic review of observational studies. *Stroke* 2007:2382–90. Doi: 10.1161/STROKEAHA.107.482760.
20 Libby P. Inflammation in atherosclerosis. *Nature* 2002;**420**(6917):868–74. Doi: 10.1038/nature01323.
21 Daemen MJ, Ferguson MS, Gijsen FJ, Hippe DS, Kooi ME, Demarco K, et al. Carotid plaque fissure: An underestimated source of intraplaque hemorrhage. *Atherosclerosis* 2016;**254**:102–8. Doi: 10.1016/j.atherosclerosis.2016.09.069.
22 Michel J-B, Luis Martin-Ventura J, Nicoletti A, Ho-Tin-Noé B. Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages 2014. Doi: 10.1016/j.atherosclerosis.2014.03.020.
23 Ribatti D, Levi-Schaffer F, Kovanen PT. Inflammatory angiogenesis in atherogenesis - A double-edged sword. *Ann Med* 2008;**40**(8):606–21. Doi: 10.1080/07853890802186913.
24 Sluimer JC, Kolodgie FD, Bijnens APJJ, Maxfield K, Pacheco E, Kutys B, et al. Thin-Walled Microvessels in Human Coronary Atherosclerotic Plaques Show Incomplete Endothelial Junctions. Relevance of Compromised Structural Integrity for Intraplaque Microvascular Leakage. *J Am Coll Cardiol* 2009;**53**(17):1517–27. Doi: 10.1016/j.jacc.2008.12.056.
25 Turpin C, Catan A, Meilhac O, Bourdon E, Canonne-Hergaux F, Rondeau P. Erythrocytes: Central Actors in Multiple Scenes of Atherosclerosis. *Int J Mol Sci* 2021;**22**(11). Doi: 10.3390/IJMS22115843.
26 Xu S. Iron and Atherosclerosis: The Link Revisited. *Trends Mol Med* 2019;**25**(8):659–61. Doi: 10.1016/j.molmed.2019.05.012.
27 Vinchi F, Muckenthaler MU, Silva MC Da, Balla G, Balla J, Jeney V. Atherogenesis and iron: from epidemiology to cellular level. *Front Pharmacol* 2014;**5**. Doi: 10.3389/FPHAR.2014.00094.
28 Jeney V, Balla G, Balla J. Red blood cell, hemoglobin and heme in the progression of atherosclerosis. *Front Physiol* 2014. Doi: 10.3389/fphys.2014.00379.
29 Wendorff C, Wendorff H, Pelisek J, Tsantilas P, Zimmermann A, Zernecke A, et al. Carotid Plaque Morphology Is Significantly Associated with Sex, Age, and History of Neurological Symptoms. *Stroke* 2015;**46**(11):3213–9. Doi: 10.1161/STROKEAHA.115.010558.
30 De Bakker M, Timmerman N, Van Koeverden ID, De Kleijn DP V, De Borst GJ, Pasterkamp G, et al. The age-and sex-specific composition of atherosclerotic plaques in vascular surgery patients 2020. Doi: 10.1016/j.atherosclerosis.2020.07.016.
31 Plank F, Beyer C, Friedrich G, Wildauer M, Feuchtner G. Sex differences in coronary artery plaque composition detected by coronary computed tomography: quantitative and qualitative analysis. *Netherlands Hear J 2019 275* 2019;**27**(5):272–80. Doi: 10.1007/S12471-019-1234-5.
32 Virmani R, Burke AP, Kolodgie FD, Farb A. Pathology of the thin-cap fibroatheroma: A type of vulnerable plaque. *J Interv Cardiol* 2003;**16**(3):267–72. Doi: 10.1034/j.1600-0854.2003.8042.x.
33 Farb A, Burke AP, Tang AL, Liang Y, Mannan P, Smialek J, et al. Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death. *Circulation* 1996;**93**(7):1354–63. Doi: 10.1161/01.CIR.93.7.1354.
34 Durand E, Scoazec A, Lafont A, Boddaert J, Al Hajzen A, Addad F, et al. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: A clue to the understanding of the mechanisms of thrombotic plaque erosion. *Circulation* 2004;**109**(21):2503–6. Doi: 10.1161/01.CIR.0000130172.62481.90.
35 Schwartz SM, Galis ZS, Rosenfeld ME, Falk E. Plaque rupture in humans and mice. *Arterioscler Thromb Vasc Biol* 2007;**27**(4):705–13. Doi: 10.1161/01.ATV.0000261709.34878.20.
36 Vittinghoff E, McCulloch CE. Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression. *Am J Epidemiol* 2007;**165**(6):710–8. Doi: 10.1093/aje/kwk052.

Figure 1. Study design and flowchart of study participants. A. Graphical illustration of the study design. Created with BioRender.com. **B.** Number of individuals included in the current study





Table 1. Baseline patient Characteristics

Variable	Overall, N = 1,819[1]	Male, N = 1,277[1]	Female, N = 542[1]	p-value[2]
Age - years	69 (9)	69 (9)	70 (10)	0.21
Systolic BP – mmHg	153 (26)	153 (25)	153 (26)	0.72
Diastolic BP – mmHg	82 (28)	82 (25)	81 (34)	0.076
Hypertension	1,345/1,787 (75%)	915/1,255 (73%)	430/532 (81%)	<0.001
Diabetes mellitus	447/1,819 (25%)	319/1,277 (25%)	128/542 (24%)	0.54
Hypercholesterolemia	1,187/1,687 (70%)	833/1,192 (70%)	354/495 (72%)	0.50
Total cholesterol – mmol/L	4.64 (3.90, 5.51)	4.50 (3.81, 5.34)	5.00 (4.03, 5.91)	<0.001
LDL – mmol/L	2.68 (2.07, 3.44)	2.60 (2.02, 3.30)	2.79 (2.20, 3.78)	0.002
HDL – mmol/L	1.12 (0.93, 1.40)	1.07 (0.90, 1.30)	1.30 (1.05, 1.60)	<0.001
Triglycerides – mmol/L	1.46 (1.07, 2.07)	1.50 (1.07, 2.10)	1.40 (1.09, 1.95)	0.19
Body Mass Index – kg/m2	26.1 (24.1, 28.7)	26.2 (24.2, 28.7)	25.7 (23.2, 28.7)	0.012
eGFR – mL/min/1.73/m2	73.2 (21.5)	74.5 (21.5)	70.3 (21.1)	<0.001
Smoking Status				<0.001
Current smoker	612/1,731 (35%)	396/1,222 (32%)	216/509 (42%)	
Ex-smoker	886/1,731 (51%)	691/1,222 (57%)	195/509 (38%)	
Never smoked	233/1,731 (13%)	135/1,222 (11%)	98/509 (19%)	
History of CAD	602/1,818 (33%)	471/1,277 (37%)	131/541 (24%)	<0.001
History of PAOD	383/1,818 (21%)	272/1,277 (21%)	111/541 (21%)	0.71
History of Peripheral interventions	381/1,812 (21%)	257/1,272 (20%)	124/540 (23%)	0.19
History of TIA/Stroke	1,426/1,819 (78%)	996/1,277 (78%)	430/542 (79%)	0.53
Use of antihypertensive drugs	1,380/1,814 (76%)	967/1,275 (76%)	413/539 (77%)	0.72
Use of statins	1,444/1,813 (80%)	1,011/1,274 (79%)	433/539 (80%)	0.64
Use of antiplatelet drugs	1,589/1,813 (88%)	1,105/1,274 (87%)	484/539 (90%)	0.070
Use of oral anticoagulants	205/1,807 (11%)	156/1,270 (12%)	49/537 (9.1%)	0.053
Ipsilateral carotid stenosis				0.021
0-50%	10/1,779 (0.6%)	7/1,245 (0.6%)	3/534 (0.6%)	
50-70%	143/1,779 (8.0%)	114/1,245 (9.2%)	29/534 (5.4%)	
70-99%	1,626/1,779 (91%)	1,124/1,245 (90%)	502/534 (94%)	
Contralateral carotid stenosis				0.41
0-50%	949/1,662 (57%)	661/1,171 (56%)	288/491 (59%)	
50-100%	713/1,662 (43%)	510/1,171 (44%)	203/491 (41%)	
Pre-procedural neurological symptoms				0.10
Asymptomatic	234/1,813 (13%)	178/1,273 (14%)	56/540 (10%)	
Ocular	334/1,813 (18%)	223/1,273 (18%)	111/540 (21%)	
TIA	754/1,813 (42%)	523/1,273 (41%)	231/540 (43%)	
Stroke	491/1,813 (27%)	349/1,273 (27%)	142/540 (26%)	
Percentage glycophorin stain[3]	5.89 (2.69, 12.08)	7.15 (3.37, 13.41)	4.06 (1.98, 8.32)	<0.001

[1]Mean (SD); n/N (%); Median (IQR)
[2]Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test
[3]Calculated as (glycophorin stain / plaque size)*100
BP = blood pressure; HDL= high density lipoprotein; LDL= low density lipoprotein; BMI= body mass index; eGFR = estimated Glomerular filtration rate; TIA = transient ischemic attack.



Figure 2. Example of slides with glycophorin C (GLYCC) staining. Displayed are example samples for diffuse glycophorin C staining for both male and female patients. Be aware of the slight differences between HE- and Glycophorin C-stained samples from the same patients, these are sequential slides.



Figure 3. Univariable association between glycophorin C expressed as percentage glycophorin of total plaque surface with presence of IPH and with overall plaque phenotype. P-values are

derived from Kruskal Wallis test. Shown are the median values (central line), the upper and lower quartiles (box limits), and the 1.5x interquartile range (whiskers). The percentage of glycophorin C (inverse rank transformed) was significantly higher in male patients compared to female patients ($p<0.001$).



Figure 4. Example of slides with different levels of Glycophorin C (GLYCC) staining compared to the presence of intraplaque hemorrhage. Displayed are example samples for low, moderate and high glycophorin C staining in samples from patients in which the presence of intraplaque hemorrhage was scored as present or not present. Be aware of the slight differences between HE- and Glycophorin C-stained samples from the same patients, these are sequential slides.



Figure 5. Multivariable associations between plaque glycophorin (1 SD increment) with intraplaque hemorrhage and pre-procedural neurological symptoms. Associations adjusted for plaque size (Model 1) and adjusted for plaque size and confounders (Model 2) are shown. Shown are odd ratios (OR) or hazard ratios (HR) and error bars corresponding to their 95% confidence intervals (CI). The confounders included in the model 2 associations can be found in **Supplemental Table 2.**

A. Multivariable associations of glycophorin with intraplaque hemorrhage, as derived from logistic regression analyses. **B.** Multivariable associations of glycophorin C with pre-procedural symptoms (asymptomatic versus symptomatic), as derived from logistic regression analyses.



Figure 6. Univariable association between glycophorin C expressed as percentage glycophorin of total plaque surface with overall plaque phenotype. P-values are derived from pairwise comparisons using Wilcoxon rank sum test. Shown are the median values (central line), the upper and lower quartiles (box limits), and the 1.5x interquartile range (whiskers). The percentage of glycophorin C (inverse rank transformed) was significantly higher in fibroatheromatous and atheromatous plaques in comparison to fibrous plaques. Additionally, the percentage of glycophorin C (inverse rank transformed) was significantly higher in Atheromatous plaques in comparison to fibroatheromatous plaques.



Figure 7. Association of glycophorin with (1 SD increment) with the individual (semi)-quantitative histopathological features (binary traits). Shown are odds ratios (OR) and error bars correspond to their 95% CI, as derived from logistic regression analyses. Blue error bars are the full cohort, and the green and red error bars are male and female subset, respectively.